United States:
HHS Releases Long-Awaited 340B Proposed Guidance
02 September 2015
McDermott Will & Emery
To print this article, all you need is to be registered or login on Mondaq.com.
On August 27, 2015, the U.S. Department of Health and Human
Services released the long-awaited and much-anticipated proposed
340B Drug Pricing Program Omnibus Guidance. This On the
Subject highlights key takeaways from the guidance
(including the significant revisions to the definitions of drugs
eligible for discounted 340B pricing and patients eligible to
receive such discounted drugs) and provides an outline of its
provisions. McDermott will host a webinar in the near
future to further discuss the proposed guidance and its
ramifications; more details will be released shortly.
Read the full On the Subject.
HHS Releases Long-Awaited 340B Proposed Guidance
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...